CLLD territory Sample Clauses

CLLD territory. Urban areas. When supporting CLLD, the priority is given to territories where ITIs and integrated sustainable urban development actions are implemented. CLLD is a mandatory part of ITIs for territories of integrated sustainable urban development actions, i.e. target territories identified in 5 major cities (up to 7 target territories, with the average population of 30,000–40,000 each). In the competitive selection of strategies other ITI implementation territories are prioritised (in the category of small and medium-sized cities, which includes cities with population over 6,000 and smaller municipal centres): identified target territories (in these areas CLLD is implemented as part of ITIs, where the CLLD strategy contributes to the integrated territorial development programme); territories related with target territories; target territories identified in 2007–2013 (territories of transitional period). CLLD-supported actions may also be implemented in other cities with population above 6,000 and smaller municipal centres (including parts of large cities, small towns and medium-sized cities where ITIs will not be implemented), where they are clearly conducive to the implementation of the Operational Programme for the EU Funds’ Investments in 2014–2020 (selecting strategies through tender). A territory of an urban LAG refers to a part of a city, a city with a population above 6 thou, a city with the status of a municipal centre, or an agglomeration of several cities, with the population above 6,000 or with the status of a municipal centre, with the total population from 6,000 to 150,000. An exception is provided for to ensure the contribution of CLLD to the implementation of ITIs in territories where integrated territorial development programmes are run, i.e. in cities with the population above 6,000 and in smaller municipal centres. The population in most of the Lithuanian municipal centres is under 10,00 (25 of 55 municipal centres). In sparsely populated areas, however, these cities perform the same functions and deal with the same challenges as larger urban centres. The aim is to implement LDSs in socially, economically, and geographically single territories, but this would be virtually impossible if geographically separated cities whose communities are not connected with each other in any way are artificially merged. In case of extraordinary conditions (very sparsely populated areas, natural obstacles, large distances to the closest city or agglomeratio...
AutoNDA by SimpleDocs

Related to CLLD territory

  • Territory 43.1 This Agreement applies to the territory in which Verizon operates as an Incumbent Local Exchange Carrier in the Commonwealth of Pennsylvania. Verizon shall be obligated to provide Services under this Agreement only within this territory.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Country and Territory Names The country and territory names (including their IDN variants, where applicable) contained in the following internationally recognized lists shall be withheld from registration or allocated to Registry Operator at All Levels:

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

Time is Money Join Law Insider Premium to draft better contracts faster.